4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InSilico Medicine Cayman TopCo (3696) operates in the Software - Infrastructure industry and is headquartered in Hong Kong, Hong Kong with about 317 employees. Its market capitalization is roughly $26 billion. In the fiscal year ended 2025-12-31, 3696 reported $56M in revenue and ($352M) in net income.
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $56M | $86M | $51M | $30M |
| Gross Profit | $46M | $78M | $39M | $19M |
| Operating Income (EBIT) | ($62M) | ($33M) | ($90M) | ($80M) |
| Net Income | ($352M) | ($17M) | ($212M) | ($222M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $490M | $144M | $203M | $235M |
| Total Liabilities | $38M | $808M | $853M | $684M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3696 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms